Laboratory strains of herpes simplex virus lacking thymidine kinase (TK) cannot replicate acutely to detectable levels in mouse trigeminal ganglia and do not reactivate from latency. However, many pathogenic clinical isolates that are resistant to the antiviral drug acyclovir are heterogeneous populations of TK-negative (TK−) and TK-positive (TK+) viruses. To recapitulate this in vivo, mice were infected with mixtures of wild-type virus and a recombinant TK− mutant in various ratios. Following co-infection, the replication, number of latent viral genomes and reactivation efficiency of TK+ virus in trigeminal ganglia were reduced in a manner related to the amount of TK− virus in the inoculum. TK+ virus did not always complement the acute replication or increase the number of latent viral genomes of TK− mutant in mouse ganglia. Even so, TK+ virus could still confer the pathogenic phenotype to a TK− mutant, somehow providing sufficient TK activity in trans to permit a TK− mutant to reactivate from latently infected ganglia.
ChenS.-H.,
CookW. J.,
GroveK. L.,
CoenD. M.1998; Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication and in mouse sensory ganglia and reactivation from latency upon explant. J Virol 72:6710–6715
ChenS.-H.,
PearsonA.,
CoenD. M.,
ChenS.-H.2004; Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J Virol 78:520–523[CrossRef]
CoenD. M.,
IrmiereA. F.,
JacobsonJ. G.,
KernsK. M.1989a; Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168:221–231[CrossRef]
CoenD. M.,
Kosz-VnenchakM.,
JacobsonJ. G.,
LeibD. A.,
BogardC. L.,
SchafferP. A.,
TylerK. L.,
KnipeD. M.1989b; Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 86:4736–4740[CrossRef]
Di StefanoG.,
CasoliT.,
FattorettiP.,
GracciottiN.,
SolazziM.,
Bertoni-FreddariC.2001; Distribution of MAP2 in hippocampus and cerebellum of young and old rats by quantitative immunohistochemistry. J Histochem Cytochem 49:1065–1066[CrossRef]
EfstathiouS.,
KempS.,
DarbyG.,
MinsonA. C.1989; The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol 70:869–879[CrossRef]
EllisM. N.,
WatersR.,
HillE. L.,
LobeD. C.,
SellesethD. W.,
BarryD. W.1989; Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother 33:304–310[CrossRef]
EnglundJ. A.,
ZimmermanM. E.,
SwierkoszE. M.,
GoodmanJ. L.,
SchollD. R.,
BalfourH. H., Jr.
1990; Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 112:416–422[CrossRef]
FieldH. J.1982; Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy. Antimicrob Agents Chemother 21:744–752[CrossRef]
FieldH. J.,
LayE.1984; Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir. Antivir Res 4:43–52[CrossRef]
GilbertC.,
Bestman-SmithJ.,
BoivinG.2002; Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 5:88–114[CrossRef]
GriffithsA.,
RenfreyS.,
MinsonT.1998; Glycoprotein C-deficient mutants of two strains of herpes simplex virus type 1 exhibit unaltered adsorption characteristics on polarized or non-polarized cells. J Gen Virol 79:807–812
HorsburghB. C.,
ChenS.-H.,
HuA.,
MulambaG. B.,
BurnsW. H.,
CoenD. M.1998; Recurrent acyclovir-resistant herpes simplex virus in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis?. J Infect Dis 178:618–625[CrossRef]
HwangC. B. C.,
HorsburghB.,
PelosiE.,
RobertsS.,
DigardP.,
CoenD. M.1994; A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant. Proc Natl Acad Sci U S A 91:5461–5465[CrossRef]
KramerM. F.,
CoenD. M.1995; Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol 69:1389–1399
LeibD. A.,
NadeauK. C.,
RundleS. A.,
SchafferP. A.1991; The promoter of the latency-associated transcripts of herpes simplex virus type 1 contains a functional cAMP-response element: role of the latency-associated transcripts and cAMP in reactivation of viral latency. Proc Natl Acad Sci U S A 88:48–52[CrossRef]
SainzB.Jr,
HalfordW. P.2002; Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 76:11541–11550[CrossRef]
SedaratiF.,
JavierR. T.,
StevensJ. G.1988; Pathogenesis of a lethal mixed infection in mice with two nonneuroinvasive herpes simplex virus strains. J Virol 62:3037–3039
TenserR. B.,
EdrisW. A.1987; Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus after in vivo complementation. J Virol 61:2171–2174
TenserR. B.,
ResselS.,
DunstanM. E.1981; Herpes simplex virus thymidine kinase expression in trigeminal ganglion infection: correlation of enzyme activity with ganglion virus titer and evidence of in vivo complementation. Virology 112:328–341[CrossRef]
ThompsonR. L.,
SawtellN. M.2000; Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral genome copy number latency. J Virol 74:965–974[CrossRef]
WellerS. K.,
AschmanD. P.,
SacksW. R.,
CoenD. M.,
SchafferP. A.1983; Genetic analysis of temperature-sensitive mutants of HSV-1: the combined use of complementation and physical mapping for cistron assignment. Virology 130:290–305[CrossRef]